{"id":"d086","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of D086 is not well understood, but it is believed to involve the inhibition of a specific enzyme involved in the disease process. This inhibition leads to a decrease in the disease symptoms.","oneSentence":"D086 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:28.105Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05657574","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-11-24","conditions":"Primary Hypercholesterolemia","enrollment":228},{"nctId":"NCT04478097","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-07-14","conditions":"Cardiovascular Disease","enrollment":51},{"nctId":"NCT04019743","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-07-28","conditions":"Hypertension, Dyslipidemias","enrollment":24},{"nctId":"NCT03583905","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-04-04","conditions":"Hypertensive Patients With Dyslipidemia","enrollment":154},{"nctId":"NCT03793985","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-09-05","conditions":"Hyperlipidemias","enrollment":45},{"nctId":"NCT03659149","phase":"PHASE1","title":"Pharmacokinetics and Safety Profile of CKD-333","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-08","conditions":"Hypertension, Dyslipidemias","enrollment":37},{"nctId":"NCT03017950","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction of CKD-330 and D086","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-12","conditions":"Hypertension, Hyperlipidemias","enrollment":83}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D086","genericName":"D086","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D086 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}